IL181301A - Compounds similar to cyclophamine and anticancer drugs containing them - Google Patents

Compounds similar to cyclophamine and anticancer drugs containing them

Info

Publication number
IL181301A
IL181301A IL181301A IL18130107A IL181301A IL 181301 A IL181301 A IL 181301A IL 181301 A IL181301 A IL 181301A IL 18130107 A IL18130107 A IL 18130107A IL 181301 A IL181301 A IL 181301A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
cancer pharmaceutical
cyclopamine analogues
cyclopamine
analogues
Prior art date
Application number
IL181301A
Other languages
English (en)
Hebrew (he)
Other versions
IL181301A0 (en
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of IL181301A0 publication Critical patent/IL181301A0/en
Publication of IL181301A publication Critical patent/IL181301A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL181301A 2004-08-27 2007-02-13 Compounds similar to cyclophamine and anticancer drugs containing them IL181301A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60502004P 2004-08-27 2004-08-27
US61717004P 2004-10-08 2004-10-08
US62567604P 2004-11-05 2004-11-05
US68316905P 2005-05-19 2005-05-19
PCT/US2005/030406 WO2006026430A2 (en) 2004-08-27 2005-08-26 Cyclopamine analogues and methods of use thereof

Publications (2)

Publication Number Publication Date
IL181301A0 IL181301A0 (en) 2007-07-04
IL181301A true IL181301A (en) 2015-10-29

Family

ID=36000609

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181301A IL181301A (en) 2004-08-27 2007-02-13 Compounds similar to cyclophamine and anticancer drugs containing them

Country Status (12)

Country Link
US (4) US7230004B2 (enExample)
EP (3) EP2316833B1 (enExample)
JP (2) JP5204486B2 (enExample)
KR (1) KR101487481B1 (enExample)
CN (1) CN102241727B (enExample)
AU (1) AU2005280112B2 (enExample)
BR (1) BRPI0514444A (enExample)
CA (1) CA2579078C (enExample)
ES (1) ES2578728T3 (enExample)
IL (1) IL181301A (enExample)
NO (1) NO341137B1 (enExample)
WO (1) WO2006026430A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20170326118A1 (en) * 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
ES2578728T3 (es) * 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) * 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
EP2066320A1 (en) * 2006-09-27 2009-06-10 Irm, Llc Methods and compositions for treating lymphoma and myeloma
TWI433674B (zh) * 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CN101687877B (zh) 2007-03-07 2014-07-23 无限发现股份有限公司 杂环环杷明类似物及其使用方法
EP2134719B1 (en) * 2007-03-07 2013-07-17 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
PE20090806A1 (es) 2007-04-18 2009-06-27 Merck & Co Inc Derivados de triazol que son antagonistas de smo
WO2009058945A1 (en) 2007-10-30 2009-05-07 The Wistar Institute Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer
US8669243B2 (en) 2007-10-30 2014-03-11 The Wistar Institute Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
WO2009086451A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US20100222287A1 (en) * 2007-12-27 2010-09-02 Mcgovern Karen J Therapeutic Cancer Treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
EP2303275A4 (en) * 2008-06-17 2012-05-09 Univ Duke STANDARD RECEPTOR MODULATORS
WO2010030948A2 (en) * 2008-09-12 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
EP2233566A1 (en) 2009-03-17 2010-09-29 Vrije Universiteit Brussel Generation of pancreatic progenitor cells
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011057222A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor
CA2782527C (en) * 2009-12-04 2019-09-17 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
CN102167812B (zh) * 2010-02-26 2016-04-20 北京科美森医药研发有限公司 聚乙二醇化环巴胺类似物及其制备方法和用途
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2011156329A2 (en) * 2010-06-11 2011-12-15 Board Of Regents, The University Of Texas System Methods of treating pain and morphine tolerance via modulation of hedgehog signalling pathway
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN105622708B (zh) 2016-02-14 2017-10-10 山东大学 治疗呼吸道合胞病毒感染的化合物及其制备方法与用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
JP2023503926A (ja) * 2019-11-22 2023-02-01 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｔａｓｐａｓｅ１阻害剤およびその使用
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT
RU2739294C1 (ru) * 2020-07-02 2020-12-22 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного рака ротоглотки
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS
CN118388576A (zh) * 2024-03-27 2024-07-26 四川大学 环巴胺的合成方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2851054B2 (ja) * 1989-03-15 1999-01-27 サントリー株式会社 ベンズオキセピン誘導体
NZ278765A (en) 1993-12-30 1998-05-27 Harvard College Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6867216B1 (en) * 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
DE60028411T2 (de) * 1999-10-13 2007-01-04 Johns Hopkins University School Of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
IL133809A0 (en) * 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
ES2623711T3 (es) * 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
AU2002247847A1 (en) * 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
JP2003192919A (ja) 2001-10-17 2003-07-09 Asahi Denka Kogyo Kk 難燃性合成樹脂組成物
GB0221539D0 (en) * 2002-09-17 2002-10-23 Medical Res Council Methods of treatment
US20080118493A1 (en) * 2003-07-15 2008-05-22 Beachy Philip A Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
US20080095761A1 (en) * 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
US20070231828A1 (en) * 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
US20080057071A1 (en) * 2003-10-20 2008-03-06 Watkins David N Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
JP4239907B2 (ja) * 2004-06-21 2009-03-18 沖電気工業株式会社 レベルシフタ回路、表示装置の駆動回路、表示装置、及び階調選択回路のストレステスト方法
ES2578728T3 (es) 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
WO2006039569A1 (en) 2004-09-30 2006-04-13 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007123511A2 (en) 2006-03-24 2007-11-01 Infinity Pharmaceuticals, Inc. Dosing regimens for the treatment of cancer
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008089123A2 (en) 2007-01-12 2008-07-24 Infinity Discovery, Inc. Methods for analysis of hedgehog pathway inhibitors
EP2134719B1 (en) * 2007-03-07 2013-07-17 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof

Also Published As

Publication number Publication date
CN102241727B (zh) 2015-03-25
AU2005280112B2 (en) 2012-07-19
EP2316833B1 (en) 2016-03-30
KR20070083602A (ko) 2007-08-24
ES2578728T3 (es) 2016-07-29
CA2579078C (en) 2016-11-22
CN102241727A (zh) 2011-11-16
US8236956B2 (en) 2012-08-07
AU2005280112A1 (en) 2006-03-09
US20110166353A1 (en) 2011-07-07
HK1157757A1 (en) 2012-07-06
KR101487481B1 (ko) 2015-01-28
JP2008511635A (ja) 2008-04-17
EP1817308A2 (en) 2007-08-15
US20070191410A1 (en) 2007-08-16
NO341137B1 (no) 2017-08-28
JP2012232997A (ja) 2012-11-29
WO2006026430A2 (en) 2006-03-09
US7230004B2 (en) 2007-06-12
US20080269272A1 (en) 2008-10-30
HK1112619A1 (en) 2008-09-12
US20060074030A1 (en) 2006-04-06
US7875628B2 (en) 2011-01-25
EP2316832B1 (en) 2017-03-08
EP2316833A1 (en) 2011-05-04
US7407967B2 (en) 2008-08-05
NO20071264L (no) 2007-05-15
CA2579078A1 (en) 2006-03-09
EP1817308B1 (en) 2014-10-08
IL181301A0 (en) 2007-07-04
EP2316832A1 (en) 2011-05-04
JP5204486B2 (ja) 2013-06-05
EP1817308A4 (en) 2007-12-26
WO2006026430A3 (en) 2006-06-22
BRPI0514444A (pt) 2008-06-10

Similar Documents

Publication Publication Date Title
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
EP1804823A4 (en) NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
IL183105A0 (en) 4-arylamino pyridone derivatives and pharmaceutical compositions containing them
IL190292A (en) History of pyridopyrimidinone and their pharmaceutical preparations
IL223545A0 (en) Pharmaceutical compositions
IL179809A0 (en) Pharmaceutical compositions
GB0408308D0 (en) Pharmaceutical compositions
NO343748B1 (no) Cyklopaminanaloger og farmasøytiske preparater omfattende slike
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
EP1909780A4 (en) AGAINST TUBERCULOSIS, COMPOSITIONS AND PROCEDURES
IL183986A0 (en) Pharmaceutical compounds and compositions
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
EP1809656A4 (en) CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS
IL181730A0 (en) Benzodiazinone derivatives and pharmaceutical compositions containing the same
PL1837019T3 (pl) Kompozycja farmaceutyczna rozpadająca się w ustach
EP1809291A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL LEVY
IL178067A0 (en) Pharmaceutical dosage forms and compositions
IL186337A0 (en) Stannsoporfin compositions and administration
EP1805154A4 (en) PHARMACEUTICAL COMPOSITIONS
IL177498A0 (en) Difluoroethoxy -substituted hydroxy-6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
IL177497A0 (en) Isoamido-substituted hydroxy-6-phenylphenanthridine derivatives and pharmaceutical compositions containing the same
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
PT2474528E (pt) Compostos antineoplásicos e composições farmacêuticas dos mesmos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed